Cartesian Therapeutics, Inc. (RNAC) Return on equity 2016–2022
Cartesian Therapeutics, Inc. (RNAC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
37.7%FY2022 · since FY2016: -65.9% → 37.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | 37.7% | +151.8 pp |
| FY2021 | -114.1% | — |
| FY2019 | -659.2% | — |
| FY2017 | -126.1% | -60.2 pp |
| FY2016 | -65.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice